BerGenBio

Selective AXL inhibitors

Home  /  Media Centre  /  Presentations

EHA 2021, Dr. Sonja Loges et al.

Share This Presentation

11 June 2021

The combination of AXL inhibitor bemcentinib and low-dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II trial (NCT02488408) 

Share This Presentation

Latest News

News

BerGenBio Reports Second Quarter and Half Year 2022 Financial Results and Provides Business Update

News

BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.